Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 5 | History Defined

3 Reliable Stocks to Fall Back on When Times Are Tough

The stock market volatility is rife amid the persistently high inflation and the Fed’s tightening monetary policy despite a slowing economy. Given such challenging times, we think it could be wise to fall back on quality stocks Cigna (CI), Agilent (A), and Flowers Foods (FLO) for safeguarding one’s portfolio. Keep…

StockNews.com

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

StockNews.com

Nigel Jones to leave CIYMS after Irish Cup final triumph over Lisburn

Captain expected to move to newly-crowned Premier League champions

Belfast Live

From analysis to the latest developments in health,
read the most diverse news in one place.

CIYMS and Lisburn aiming for first Irish Cup final triumph

Northern Cricket Union clubs go head-to-head in showpiece at Bready

Belfast Live

3 Blue-Chip Stocks That'll Help Your Portfolio Survive

Thanks to better-than-expected corporate earnings and the expectation that inflation will cool off, the stock market rebounded from the lows in the year's first half. However, inflation remains elevated, so the Fed is expected to continue its aggressive interest rate hikes. Given this backdrop, investors could cushion their portfolios by…

StockNews.com

What Are Whales Doing With Cigna

Someone with a lot of money to spend has taken a bearish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Monkeypox in Australia: should you be worried? And who can get the vaccine?

On July 23, World Health Organisation Director-General Tedros Adhanom Ghebreyesus took the unprecedented step and declared the monkeypox outbreak a “public health emergency of international concern” – the highest global alert level for a disease outbreak.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Looking At Cigna's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 13 strange trades.

Benzinga

A Houston Drug Cop's Lies Sent This Man to Prison for 25 Years

The case shows how lax supervisors, incurious prosecutors, deferential judges, credulous jurors, and inattentive defense attorneys abet police misconduct.

Reason

Council-run care home did not provide 'basic care hours' for residents

A COUNCIL-RUN care home did not have enough staff to “even provide basic care hours” despite workers taking on extra shifts and overtime, an…

The National (Scotland)

East Lothian care home given 'weak' grading after scathing inspection

The council-run care home has a reputation for high inspection grades but the Care Inspectorate said changes were need to provude 'safe staffing levels'

Edinburgh Live

3 Stocks to Target as Investors Rotate Back Into the Health Care Sector

Investors seem to show renewed interest in the healthcare sector as COVID-19 cases rise worldwide and portfolio resiliency amid the uncertain macro environment. So, fundamentally strong healthcare stocks Cigna Corp (CI), Centene Corp (CNC), and Humana (HUM) might be solid buys now. Read on.

StockNews.com

Is This "Strong Buy" Health Insurance Company a Bargain?

Healthcare company Elevance Health (ELV) reported solid revenue growth in the last reported quarter. While the stock trades at a discount to its peers, analysts expect the company’s financials to improve. So, let’s evaluate if it would be wise to buy the stock now. Read on.

StockNews.com

3 Winning Healthcare Stocks to Buy for the Rest of the Summer

Increased health awareness and the rapidly aging population are expected to drive the growth of healthcare companies. Healthcare stocks Cigna Corp. (CI), Humana (HUM), and McKesson Corp. (MCK) have bucked the market downtrend and are in momentum. Since the market is expected to remain under pressure in the near term,…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Much You Would Have Made Owning Cigna Stock In The Last 10 Years

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 9.15% on an annualized basis producing an average annual return of 20.13%. Currently, Cigna has a market capitalization of $84.90 billion.

Benzinga

Morgan Stanley Upgrades Cigna On Humira Prospects

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

StockNews.com

3 Attractive 'Growth at a Reasonable Price' Stocks to Buy Now

GARP is a strategy to blend the best parts of value and growth investing. It's particularly apt as it will allow investors to identify the top growth stocks trading at attractive valuations such as Cigna (CI), Freeport McMoran (FCX), and Micron (MU).

StockNews.com

3 Attractive 'Growth at a Reasonable Price' Stocks to Buy Now

Growth stocks have been mired in a brutal bear market. However, a handful of stocks are quite cheap and continue to grow at an impressive rate. 3 such stocks that investors should consider buying are Cigna (CI), Micron (MU), and Freeport McMoran (FCX).

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With Cigna

Someone with a lot of money to spend has taken a bullish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Red-Hot Healthcare Stocks Ignoring the Market's Downtrend

Despite bearish market sentiment, the healthcare industry has outperformed the broader market thanks to its defensive nature. Given overwhelming demand and the need for global healthcare development, we think the stocks of quality healthcare companies Cigna (CI), Organon (OGN), and Bristol-Myers Squibb (BMY) could be solid bets now. These stocks…

Benzinga

$1000 Invested In Cigna 10 Years Ago Would Be Worth This Much

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 7.87% on an annualized basis producing an average annual return of 19.99%. Currently, Cigna has a market capitalization of $86.15 billion.

StockNews.com

5 Life Insurance Stocks to Buy Hand Over Fist

U.S. Treasury yields rose to multi-year highs earlier this month. And rising Treasury yields along with the Fed’s interest rate hikes bode well for life insurance companies. Thus, we think the shares of fundamentally sound life insurance companies Anthem (ANTM), Cigna Corp. (CI), UnitedHealth Group (UNH), Molina Healthcare (MOH), and…

StockNews.com

5 Outperforming Health Insurance Stocks Rated 'Strong Buy'

Demand for health insurance policies has soared over the past couple of years and is projected to continue rising amid heightened health awareness in the post-pandemic era. Thus, we think the stocks of quality health insurance companies Humana (HUM), Cigna (CI), Centene (CNC), Molina Healthcare (MOH), and Anthem (ANTM) could…

StockNews.com

5 Blue-Chip Stocks Outperforming the Market in 2022

The stock market closed in the red yesterday as concerns about inflation again spooked investors. Blue-chip stocks are known for their rich history of sustained gains. Hence, we think blue-chip names Walmart (WMT), AbbVie (ABBV), Cigna Corp (CI), International Business Machines (IBM), and Johnson & Johnson (JNJ), whose stocks have…

Benzinga

Here's Why RBC Capital Raised Price Target On Cigna

Cigna Corp (NYSE:CI) posted 1Q22 adjusted EPS well above expectations on enterprise-wide growth, with a particularly solid performance in specialty pharmacy and better than expected MCR on lower testing and treatment costs. The company raised FY22 guidance on 1Q outperformance. The analysts raised the price target to $272 from $235, with a Sector Perform rating. …

1 … 3 4 5 6

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.